Nexelis Company
Nexelis has formed a consortium with eTheRNA, EpiVax, REPROCELL and CEV to develop the vaccine and help accelerate progress towards clinical trials; patient enrolment is expected in early 2021.
Technology:
COVID
Industry:
Vaccine/Drug
Headquarters:
Canada
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership